Postoperative Insulin-Like Growth Factor 1 Levels Reflect the Graft's Function and Predict Survival after Liver Transplantation

PLoS One. 2015 Jul 17;10(7):e0133153. doi: 10.1371/journal.pone.0133153. eCollection 2015.

Abstract

Background: The reduction of insulin-like growth factor 1 (IGF-1) plasma levels is associated with the degree of liver dysfunction and mortality in cirrhotic patients. However, little research is available on the recovery of the IGF-1 level and its prognostic role after liver transplantation (LT).

Methods: From April 2010 to May 2011, 31 patients were prospectively enrolled (25/6 M/F; mean age±SEM: 55.2±1.4 years), and IGF-1 serum levels were assessed preoperatively and at 15, 30, 90, 180 and 365 days after transplantation. The influence of the donor and recipient characteristics (age, use of extended criteria donor grafts, D-MELD and incidence of early allograft dysfunction) on hormonal concentration was analyzed. The prognostic role of IGF-1 level on patient survival and its correlation with routine liver function tests were also investigated.

Results: All patients showed low preoperative IGF-1 levels (mean±SEM: 29.5±2.1), and on postoperative day 15, a significant increase in the IGF-1 plasma level was observed (102.7±11.7 ng/ml; p<0.0001). During the first year after LT, the IGF-1 concentration remained significantly lower in recipients transplanted with older donors (>65 years) or extended criteria donor grafts. An inverse correlation between IGF-1 and bilirubin serum levels at day 15 (r = -0.3924, p = 0.0320) and 30 (r = -0.3894, p = 0.0368) was found. After multivariate analysis, early (within 15 days) IGF-1 normalization [Exp(b) = 3.913; p = 0.0484] was the only prognostic factor associated with an increased 3-year survival rate.

Conclusion: IGF-1 postoperative levels are correlated with the graft's quality and reflect liver function. Early IGF-1 recovery is associated with a higher 3-year survival rate after LT.

MeSH terms

  • Biomarkers / blood
  • Biomarkers / metabolism
  • Female
  • Graft Survival*
  • Human Growth Hormone / blood
  • Humans
  • Insulin-Like Growth Factor I / metabolism*
  • Liver Transplantation* / adverse effects
  • Male
  • Middle Aged
  • Patient Outcome Assessment
  • Postoperative Period
  • Risk Factors
  • Time Factors
  • Tissue Donors

Substances

  • Biomarkers
  • Human Growth Hormone
  • Insulin-Like Growth Factor I

Grants and funding

The authors have no support or funding to report.